Published in Proc Natl Acad Sci U S A on December 01, 2009
Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev (2011) 1.67
Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev (2011) 1.56
(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol (2011) 1.39
Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J Biol Chem (2011) 1.31
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals. Beilstein J Org Chem (2011) 1.17
Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proc Natl Acad Sci U S A (2010) 1.12
Classification of scaffold-hopping approaches. Drug Discov Today (2011) 1.04
Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids. J Lipid Res (2012) 1.02
Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. Mol Pharmacol (2010) 0.96
Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry (2010) 0.94
Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer. J Biol Chem (2013) 0.92
Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes. ACS Med Chem Lett (2012) 0.91
Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A (2014) 0.91
Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) (2012) 0.84
Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling. J Cheminform (2015) 0.83
Structural basis for L-lysine feedback inhibition of homocitrate synthase. J Biol Chem (2010) 0.83
Using pharmacokinetic principles to optimize pain therapy. Nat Rev Rheumatol (2010) 0.83
Different Fatty Acids Compete with Arachidonic Acid for Binding to the Allosteric or Catalytic Subunits of Cyclooxygenases to Regulate Prostanoid Synthesis. J Biol Chem (2015) 0.82
Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2. J Biol Chem (2015) 0.82
Chemically Aware Model Builder (camb): an R package for property and bioactivity modelling of small molecules. J Cheminform (2015) 0.82
Cyclooxygenase-2 catalysis and inhibition in lipid bilayer nanodiscs. Arch Biochem Biophys (2014) 0.81
Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib. Bioorg Med Chem Lett (2013) 0.80
Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1. Pharmacogenet Genomics (2012) 0.80
Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis (2013) 0.80
Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry. Biochemistry (2016) 0.80
Impairment of aspirin antiplatelet effects by non-opioid analgesic medication. World J Cardiol (2015) 0.77
Prospective performance evaluation of selected common virtual screening tools. Case study: Cyclooxygenase (COX) 1 and 2. Eur J Med Chem (2015) 0.77
Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease. Clin Proteomics (2016) 0.75
Etoricoxibium picrate. Acta Crystallogr Sect E Struct Rep Online (2010) 0.75
Computational Drug Target Screening through Protein Interaction Profiles. Sci Rep (2016) 0.75
Aspirin modulates innate inflammatory response and inhibits the entry of Trypanosoma cruzi in mouse peritoneal macrophages. Mediators Inflamm (2014) 0.75
Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation. Br J Clin Pharmacol (2015) 0.75
Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit. J Biol Chem (2016) 0.75
Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response. Antimicrob Agents Chemother (2014) 0.75
A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res (2007) 37.31
Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr (2005) 29.38
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2004) 23.86
PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends Biochem Sci (1997) 12.04
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Automated analysis of interatomic contacts in proteins. Bioinformatics (1999) 5.60
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1997) 5.11
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Control of oxygenation in lipoxygenase and cyclooxygenase catalysis. Chem Biol (2007) 2.29
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem Rev (2003) 1.93
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol (1996) 1.92
The productive conformation of arachidonic acid bound to prostaglandin synthase. Science (2000) 1.85
Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem (1985) 1.78
Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther (1994) 1.75
Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A (1994) 1.69
Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry (2009) 1.61
Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers. J Biol Chem (2009) 1.60
Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci U S A (2006) 1.49
The cyclooxygenase reaction mechanism. Biochemistry (2002) 1.38
Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J Biol Chem (2008) 1.26
Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem Sci (2007) 1.19
Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol (1999) 1.17
Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation (2001) 1.16
Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J Biol Chem (2007) 1.16
The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. J Biol Chem (1999) 1.15
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J (2001) 1.14
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A (2001) 1.13
Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol (2007) 1.10
The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol (2008) 1.09
Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J (2006) 1.03
Prostaglandin endoperoxide H synthases: peroxidase hydroperoxide specificity and cyclooxygenase activation. J Biol Chem (2007) 1.03
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol (2002) 1.00
Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr Med Chem (2008) 0.96
A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol (2000) 0.92
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol (2008) 0.91
PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim Biophys Acta (1999) 0.90
Crystal structure of arachidonic acid bound to a mutant of prostaglandin endoperoxide H synthase-1 that forms predominantly 11-hydroperoxyeicosatetraenoic acid. J Biol Chem (2004) 0.89
Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs. Eur J Pharmacol (2001) 0.89
On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. Eur J Pharmacol (2002) 0.85
Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed Chromatogr (2008) 0.84
The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther (2006) 0.83
The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol (2005) 3.93
Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nat Struct Mol Biol (2007) 3.77
Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev (2005) 2.56
Molecular recognition of histone H3 by the WD40 protein WDR5. Nat Struct Mol Biol (2006) 2.55
Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol (2006) 2.18
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
Histone modifying enzymes: structures, mechanisms, and specificities. Biochim Biophys Acta (2008) 2.07
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest (2010) 1.78
Microvascular permeabilization and cardiomyocyte injury provoked by myocardial contrast echocardiography in a canine model. J Am Coll Cardiol (2006) 1.78
A coupled fluorescent assay for histone methyltransferases. Anal Biochem (2005) 1.76
The Cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. Cell Host Microbe (2010) 1.76
Structural origins for the product specificity of SET domain protein methyltransferases. Proc Natl Acad Sci U S A (2008) 1.72
Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers. J Biol Chem (2009) 1.60
Catalytic roles for carbon-oxygen hydrogen bonding in SET domain lysine methyltransferases. J Biol Chem (2006) 1.53
Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res (2007) 1.52
Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci U S A (2006) 1.49
The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem (2006) 1.44
Calmodulin methyltransferase is an evolutionarily conserved enzyme that trimethylates Lys-115 in calmodulin. Nat Commun (2010) 1.40
Carbon-oxygen hydrogen bonding in biological structure and function. J Biol Chem (2012) 1.35
Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J Biol Chem (2011) 1.31
Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem (2008) 1.26
Human SFMBT is a transcriptional repressor protein that selectively binds the N-terminal tail of histone H3. FEBS Lett (2007) 1.25
Activation of estrogen receptor-alpha protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2005) 1.24
Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model. Thromb Haemost (2010) 1.23
Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J Immunol (2006) 1.20
X-ray absorption spectroscopy of the zinc-binding sites in the class B2 metallo-beta-lactamase ImiS from Aeromonas veronii bv. sobria. Biochemistry (2006) 1.19
Regulation of H3K4 trimethylation via Cps40 (Spp1) of COMPASS is monoubiquitination independent: implication for a Phe/Tyr switch by the catalytic domain of Set1. Mol Cell Biol (2009) 1.18
The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther (2004) 1.17
Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J Biol Chem (2007) 1.16
Kinetic manifestation of processivity during multiple methylations catalyzed by SET domain protein methyltransferases. Biochemistry (2007) 1.16
Substrate and product specificities of SET domain methyltransferases. Epigenetics (2011) 1.15
Histone-modifying enzymes: encrypting an enigmatic epigenetic code. Curr Opin Struct Biol (2006) 1.14
Structure and function of histone H3 lysine 9 methyltransferases and demethylases. Chembiochem (2011) 1.13
Structural analysis of the core COMPASS family of histone H3K4 methylases from yeast to human. Proc Natl Acad Sci U S A (2011) 1.12
Are ECG premature complexes induced by ultrasonic cavitation electrophysiological responses to irreversible cardiomyocyte injury? Ultrasound Med Biol (2011) 1.11
Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev (2002) 1.10
High-field EPR study of tyrosyl radicals in prostaglandin H(2) synthase-1. Biochemistry (2002) 1.08
Thermodynamic product retrieval methodology and validation for NAST-I. Appl Opt (2002) 1.08
Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev (2007) 1.04
Prostaglandin endoperoxide H synthases: peroxidase hydroperoxide specificity and cyclooxygenase activation. J Biol Chem (2007) 1.03
Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids. J Lipid Res (2012) 1.02
SET7/9 catalytic mutants reveal the role of active site water molecules in lysine multiple methylation. J Biol Chem (2010) 1.01
17Beta-estradiol as a receptor-mediated cardioprotective agent. J Pharmacol Exp Ther (2003) 1.00
Structural and functional analysis of JMJD2D reveals molecular basis for site-specific demethylation among JMJD2 demethylases. Structure (2012) 1.00
Direct evidence for methyl group coordination by carbon-oxygen hydrogen bonds in the lysine methyltransferase SET7/9. J Biol Chem (2011) 0.99
C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther (2002) 0.98
Estrogen-mediated protection in myocardial ischemia-reperfusion injury. Cardiovasc Toxicol (2008) 0.98
Conservation and functional importance of carbon-oxygen hydrogen bonding in AdoMet-dependent methyltransferases. J Am Chem Soc (2013) 0.97
Synthesis of four isomers of parinaric acid. Chem Phys Lipids (2004) 0.97
Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J Immunol (2007) 0.97
Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. Mol Pharmacol (2010) 0.96
A procedure for preparing oxazolines of highly unsaturated fatty acids to determine double bond positions by mass spectrometry. J Lipid Res (2003) 0.96
Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry (2010) 0.94
Crystal structure and functional analysis of homocitrate synthase, an essential enzyme in lysine biosynthesis. J Biol Chem (2009) 0.93
Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer. J Biol Chem (2013) 0.92
Electrolytic inferior vena cava model (EIM) of venous thrombosis. J Vis Exp (2011) 0.91
Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol (2005) 0.90
Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther (2004) 0.90
Rubisco in complex with Rubisco large subunit methyltransferase. Proc Natl Acad Sci U S A (2009) 0.90
Crystal structure and functional analysis of JMJD5 indicate an alternate specificity and function. Mol Cell Biol (2012) 0.90
Crystal structure of arachidonic acid bound to a mutant of prostaglandin endoperoxide H synthase-1 that forms predominantly 11-hydroperoxyeicosatetraenoic acid. J Biol Chem (2004) 0.89
Apoptosis in myocardial infarction. Ann Med (2002) 0.89
Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression. J Pharmacol Exp Ther (2005) 0.89
Fluorescent n-3 and n-6 very long chain polyunsaturated fatty acids: three-photon imaging in living cells expressing liver fatty acid-binding protein. J Biol Chem (2010) 0.89
Effect of cyclooxygenase genotype and dietary fish oil on colonic eicosanoids in mice. J Nutr Biochem (2011) 0.87
Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am J Physiol Heart Circ Physiol (2007) 0.87
Calmodulin binds RalA and RalB and is required for the thrombin-induced activation of Ral in human platelets. J Biol Chem (2002) 0.87
Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J Pharmacol Exp Ther (2005) 0.87
Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis (2007) 0.87
Purification and assay protocols for obtaining highly active Jumonji C demethylases. Anal Biochem (2011) 0.86
Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther (2004) 0.86
A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation. J Pharmacol Exp Ther (2006) 0.85
Cardiac arrhythmia and injury induced in rats by burst and pulsed mode ultrasound with a gas body contrast agent. J Ultrasound Med (2009) 0.85
Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. Pharmacology (2008) 0.84
Smooth muscle protein 22 alpha-Cre is expressed in myeloid cells in mice. Biochem Biophys Res Commun (2012) 0.84
Estrogen protects the heart from ischemia-reperfusion injury via COX-2-derived PGI2. J Cardiovasc Pharmacol (2008) 0.84
Direct enzymatic assay for %HbA1c in human whole blood samples. Clin Biochem (2008) 0.84
HBI-3000 prevents secondary sudden cardiac death. J Cardiovasc Pharmacol Ther (2013) 0.84
Application of a high-throughput fluorescent acetyltransferase assay to identify inhibitors of homocitrate synthase. Anal Biochem (2010) 0.83
Structural basis for L-lysine feedback inhibition of homocitrate synthase. J Biol Chem (2010) 0.83
Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol (2006) 0.83
Two pathways for cyclooxygenase-2 protein degradation in vivo. J Biol Chem (2009) 0.83
Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel. J Pharmacol Exp Ther (2004) 0.82
The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism. J Cardiovasc Pharmacol (2007) 0.82
Crystal structure of homoisocitrate dehydrogenase from Schizosaccharomyces pombe. Proteins (2011) 0.81
Chemical C2-elongation of polyunsaturated fatty acids. Chem Phys Lipids (2006) 0.80
Critical role of transmethylation in TLR signaling and systemic lupus erythematosus. Clin Immunol (2013) 0.80
Manipulating unconventional CH-based hydrogen bonding in a methyltransferase via noncanonical amino acid mutagenesis. ACS Chem Biol (2014) 0.80